Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDEAS-B: nebulized dexmedetomidine for pain management during burn dressing changes
ACTRN12623001033639Phase 3Completed
- Sponsor
- Metro North Health
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of dexmedetomidine in burn injury (2 arms), sponsored by Metro North Health. Primary endpoints: Adherence and acceptance of nebulization procedure and Safety and adverse events. Started Oct 2023; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
burn injury
Beyond the preview
Go deeper on ACTRN12623001033639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623001033639.